Immune checkpoint therapy in pediatric and adolescent lymphomas

Area of Science:

• Oncology
• Immunotherapy
• Pediatric Hematology-Oncology

Background:

• Immune checkpoint therapy (ICT) activates T-lymphocytes to fight cancer.
• CTLA-4 and PD-1 inhibition are key ICT strategies, enhancing anti-tumor immunity.
• ICT is highly effective in pediatric Hodgkin lymphoma, with ongoing research in other subtypes.

Purpose of the Study:

• To explore the potential of ICT in pediatric mature B-cell lymphomas.
• To identify pediatric non-Hodgkin lymphoma subtypes with PD-L1 expression suitable for ICT.
• To review current clinical trials investigating ICT in specific pediatric lymphomas.

Main Methods:

• Review of current literature and clinical trial data on ICT in pediatric lymphomas.
• Analysis of PD-L1 expression in various pediatric mature B-cell and T-cell lymphomas.
• Identification of ongoing clinical trials evaluating ICT in primary mediastinal B-cell lymphoma (PMBCL), anaplastic large cell lymphoma (ALCL), and others.

Main Results:

• Pediatric Hodgkin lymphoma shows remarkable response to ICT.
• PMBCL, ALCL, ANKL, and PTCL, NOS consistently express PD-L1, supporting ICT use.
• A Phase III trial of nivolumab in newly diagnosed PMBCL is complete, with results pending.

Conclusions:

• ICT holds significant promise for pediatric non-Hodgkin lymphomas with high PD-L1 expression.
• Ongoing trials are evaluating ICT efficacy in ALCL and ANKL.
• Further research into ICT for pediatric mature B-cell lymphomas is warranted.